AstraZeneca and Daiichi Sankyo have welcomed the confirmation that the PBS listing of ENHERTU (trastuzumab deruxtecan) will be expanded on 1 September to include more women with a form of metastatic breast cancer.
'We will continue to advocate for earlier, faster, fairer access to medicines for the benefit of all Australians'
August 29, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
OncoSil completes first production run at new Sydney manufacturing facility
December 17, 2025 - - Australian Biotech -
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 - - Australian Biotech -
Novartis names new Country President following leadership transition
December 16, 2025 - - Latest News -
Mayne Pharma opens expanded manufacturing facility after termination of takeover
December 16, 2025 - - Latest News -
Budget update includes impact of listings, but generally not much else
December 16, 2025 - - Latest News -
The UK reconfirms the direct impact of the transatlantic shift in medicine pricing
December 16, 2025 - - Latest News -
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News
